Neo-adjuvant chemotherapy (NAC) is increasingly employed in the treatment of locally advanced gastric cancer (LAGC) to enhance surgical outcomes and improve survival rates. This study aims to evaluate the efficacy of NAC in improving treatment outcomes for patients with LAGC. A retrospective analysis was conducted on a cohort of patients diagnosed with LAGC who received NAC followed by surgical resection. Treatment outcomes were measured in terms of overall survival (OS), disease-free survival (DFS), and pathological response. Our findings indicate a significant improvement in both OS and DFS among patients who received NAC compared to those who underwent surgery alone. Furthermore, a notable proportion of patients achieved a complete pathological response, correlating with improved long-term outcomes. These results underscore the potential of NAC as a vital component of the multidisciplinary treatment approach for LAGC, warranting further investigation in larger, prospective clinical trials.

Neo-Adjuvant Chemotherapy (NAC), Locally Advanced Gastric Cancer (LAGC), Treatment Outcomes

D.T. Dempsey, Stomach, in: F.C. Brunicardi, D.K. Andersen, T.R. Billiar, D.L. Dunn, J.G. Hunter, J.B. Matthews, et al. (Eds.), Schwartz's Principles of Surgery, McGraw-Hill, New York, 2010, pp. 931e935.

D.M. Mahvi, S.B. Krantz, Stomach, in: C.M. Townsend, R.D. Beauchamp, M. Evers, K.L. Mattox (Eds.),Sabiston Textbook of Surgery, Elsevier Saunders, New York, 2012, pp. 1198e1217.

J.T. Langell, S.J. Mulvihill, Gastric adenocarcinoma and other gastric neoplasms (except gastrointestinal stromal tumors), in: M.J. Zinner, Ashley (Eds.), Maingot's Abdominal Operations, McGraw-Hill, China, 2013, pp. 463e488.

S.H. Patel, D.A. Kooby, Gastric adenocarcinoma surgery and adjuvant therapy, Surg. Clin. N. Am. 91 (5) (2011) 1039e1077.

H.H. Hartgrink, C.J. van de Velde, H. Putter, I. Songun, M.E. Tesselaar, and E.K. Kranenbarg, et al., Neo-adjuvant chemotherapy for operable gastriccancer: long term results of the Dutch randomised FAMTX trial, Eur. J. Surg.Oncol. 30 (6) (2004) 643e649.

M.L. Hansen, E. Fallentin, C. Lauridsen, I. Law, B. Federspiel, L. Bæksgaard, et al., Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer e a prospective study, PLoS One 9 (5)(2014) e97605.

M.G. Guo, Q. Zheng, J. Zhong Di, Z. Yang, Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma, World J. Surg.Oncol. 12 (1) (2014) 150.

E. Oki, Y. Emi, T. Kusumoto, Y. Sakaguchi, M. Yamamoto, N. Sadanaga, et al.,Phase II study of docetaxel andS-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer, Ann. Surg. Oncol. 21 (7)(2014)2340e2346.

P. Del Rio, M. Rocchi, P. Dell'Abate, F. Pucci, C. Mazzetti, M. Sianesi, Advanced stage gastric cancer andNeoadjuvant chemotherapy: our experience in surgical resectability, Ann. Ital. Chir. 84 (6) (2013) 623e629.

T. Nagahama, M. Ando, R. Seki, K. Fujiya, H. Amagasa, J. Takasaki, et al., Preoperative chemotherapy for advanced gastric cancer, Gan To Kagaku Ryoho40 (12) (2013) 2217e2219.

A.M. Lowy, P.F. Mansfield, S.D. Leach, R. Pazdur, P. Dumas, J.A. Ajani, Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer, Ann. Surg. 229 (3) (1999) 303e308.

Kaptein AA, Morita S, Sakamoto J: Quality of life in gastric cancer.World J Gastroenterol 2005, 11:3189-3196.